SPDR S&P Pharmaceuticals ETF
XPH
XPH
72 hedge funds and large institutions have $101M invested in SPDR S&P Pharmaceuticals ETF in 2024 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
more funds holding
Funds holding: →
3% more capital invested
Capital invested by funds: $98.4M → $101M (+$2.49M)
52% less call options, than puts
Call options by funds: $813K | Put options by funds: $1.69M
Holders
72
Holding in Top 10
–
Calls
$813K
Puts
$1.69M
Top Buyers
| 1 | +$21.7M | |
| 2 | +$11.4M | |
| 3 | +$2.39M | |
| 4 |
Envestnet Portfolio Solutions
Chicago,
Illinois
|
+$2.14M |
| 5 |
JPMorgan Chase & Co
New York
|
+$2.07M |
Top Sellers
| 1 | -$35.5M | |
| 2 | -$2.15M | |
| 3 | -$1.22M | |
| 4 |
GS
GTS Securities
New York
|
-$1.12M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$964K |